DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination
Por:
Hu X., Valentin A., Cai Y., Dayton F., Rosati M., Ramírez-Salazar E.G., Kulkarni V., Broderick K.E., Sardesai N.Y., Wyatt L.S., Earl P.L., Moss B., Mullins J.I., Pavlakis G.N., Felber B.K.
Publicada:
1 ene 2018
Resumen:
DNA-based vaccines able to induce efficient cytotoxic T-cell responses targeting conserved elements (CE) of human immunodeficiency virus type 1 (HIV-1) Gag have been developed. These CE were selected by stringent conservation, the ability to induce T-cell responses with broad human leukocyte antigen coverage, and the association between recognition of CE epitopes and viral control in HIV-infected individuals. Based on homology to HIV, a simian immunodeficiency virus p27 gag CE DNA vaccine has also been developed. This study reports on the durability of the CE-specific T-cell responses induced by HIV and simian immunodeficiency virus CE DNA-based prime/boost vaccine regimens in rhesus macaques, and shows that the initially primed CE-specific T-cell responses were efficiently boosted by a single CE DNA vaccination after the long rest period (up to 2 years). In another cohort of animals, the study shows that a single inoculation with non-replicating recombinant Modified Vaccinia Ankara (rMVA62B) also potently boosted CE-specific responses after around 1.5 years of rest. Both CE DNA and rMVA62B booster vaccinations increased the magnitude and cytotoxicity of the CE-specific responses while maintaining the breadth of CE recognition. Env produced by rMVA62B did not negatively interfere with the recall of the Gag CE responses. rMVA62B could be beneficial to further boosting the immune response to Gag in humans. Vaccine regimens that employ CE DNA as a priming immunogen hold promise for application in HIV prevention and therapy. © Xintao Hu et al. abc2018.
Filiaciones:
Hu X.:
Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, P.O. Box B., Building 535, Room 206, Frederick, MD 21702-1201, United States
Valentin A.:
Human Retrovirus Section, National Cancer Institute, Frederick, MD, United States
Cai Y.:
Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, P.O. Box B., Building 535, Room 206, Frederick, MD 21702-1201, United States
Dayton F.:
Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, P.O. Box B., Building 535, Room 206, Frederick, MD 21702-1201, United States
Rosati M.:
Human Retrovirus Section, National Cancer Institute, Frederick, MD, United States
Ramírez-Salazar E.G.:
Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, P.O. Box B., Building 535, Room 206, Frederick, MD 21702-1201, United States
Kulkarni V.:
Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, P.O. Box B., Building 535, Room 206, Frederick, MD 21702-1201, United States
Broderick K.E.:
Inovio Pharmaceuticals Inc., Plymouth Meeting, PA, United States
Sardesai N.Y.:
Inovio Pharmaceuticals Inc., Plymouth Meeting, PA, United States
Wyatt L.S.:
Laboratory of Viral Diseases, NIAID, Bethesda, MD, United States
Earl P.L.:
Laboratory of Viral Diseases, NIAID, Bethesda, MD, United States
Moss B.:
Laboratory of Viral Diseases, NIAID, Bethesda, MD, United States
Mullins J.I.:
University of Washington, Seattle, WA, United States
Pavlakis G.N.:
Human Retrovirus Section, National Cancer Institute, Frederick, MD, United States
Felber B.K.:
Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, P.O. Box B., Building 535, Room 206, Frederick, MD 21702-1201, United States
|